Test an immune marker in primary Sjögren’s disease activity
Treatments studied
Part of Bones, joints & muscles, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This study looks at an immune reaction (called anti-Ro/SSA IgE) to see how active primary Sjögren’s disease is. It may help doctors better understand what’s driving symptoms and activity levels over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have primary Sjögren’s syndrome (not Sjögren’s caused by another condition)
- You can read, understand, and sign the study consent form
- You’re willing and able to return for all required follow-up visits and exams
- You do not have other major autoimmune diseases (for example rheumatoid arthritis or ANCA vasculitis)
- You have not taken certain immune-targeting medicines in the last 6 months (including abatacept, sifalimumab, rontalizumab, anifrolumab, belimumab, TNF blockers, or interferon)
- You do not have signs or symptoms of an active infection right now
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called ICP-488 for people with primary Sjögren's syndrome. It may help reduce symptoms like dry eyes and dry mouth by calming the immune system. The trial lasts about 48 weeks and includes regular check-ups.
This study follows adults with primary Sjögren’s syndrome. It may help researchers understand the condition better by using information from people who have already joined the earlier ASSESS study.
This trial studies whether iguratimod improves symptoms in people with primary Sjögren’s syndrome, and checks how safe it is. It focuses on people with confirmed disease markers (anti-SSA/Ro-60) and ongoing dry eyes and dry mouth.
This study looks at whether the level of a specific antibody (anti-Ro52) in your blood can predict how Sjögren's syndrome will progress. If you have Sjögren's and have had this blood test, the study may help doctors better understand your condition and tailor your care.
This Phase 2 study tests how to measure changes in primary Sjögren’s syndrome symptoms and body activity. It may help researchers confirm which outcomes best reflect improvement and how different patient types respond to treatment.
This study tests an investigational drug called CM336 for people with active Sjögren's syndrome. It aims to see if the drug is safe and effective in reducing symptoms like joint pain and dryness when other treatments haven't worked well.
Hear when a new Primary Sjögren's Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.